GLP-1 and Muscle:
What You Need to Protect.

The Muscle Loss Problem

Clinical trials for GLP-1 medications consistently show significant weight loss. What they also show — when body composition is assessed rather than just total weight — is that a portion of that weight loss comes from lean mass, not just fat. In the STEP trials, approximately 39% of weight lost by semaglutide participants came from lean body mass. For tirzepatide, that number was approximately 28% in the SURMOUNT trial — better, but still meaningful.

This is not unique to GLP-1 drugs. Any significant caloric deficit, particularly a rapid one, produces some lean mass loss alongside fat loss. But because GLP-1 therapy can produce very rapid and substantial caloric restriction — more than patients might achieve willfully — the lean mass impact can be more pronounced than with conventional dietary approaches.

Why Muscle Loss Matters

Muscle mass is metabolically active tissue. Every pound of muscle you carry burns approximately 6 calories per day at rest — fat burns approximately 2. This may sound modest, but at scale, muscle mass is a meaningful driver of your basal metabolic rate. Patients who lose significant lean mass during GLP-1 therapy often find that their metabolic rate drops proportionally, making maintenance harder and weight regain more likely when therapy is discontinued.

Beyond metabolic rate, lean mass matters for physical function, bone density, insulin sensitivity, and long-term healthspan. Preserving it during a weight loss protocol is not an aesthetic preference — it is a clinical priority.

What Actually Preserves Lean Mass

Protein intake. Adequate protein is the single most important nutritional variable for lean mass preservation during caloric deficit. Current evidence supports a target of approximately 1 gram of protein per pound of lean body mass per day — or approximately 0.7 grams per pound of total body weight for most patients. GLP-1 therapy reduces appetite significantly, and patients must be intentional about hitting protein targets even when overall food intake is reduced.

Resistance training. Progressive resistance training provides the mechanical stimulus that signals muscle preservation to the body. Patients who maintain a resistance training practice during GLP-1 therapy consistently show better lean mass outcomes than those who rely on cardio or are sedentary. Two to three sessions per week targeting major muscle groups is sufficient — more is not necessarily better during significant caloric restriction.

Avoiding excessive caloric restriction. GLP-1 therapy can dramatically reduce appetite. Some patients eat far less than their clinical provider intended — not because they are disciplined, but because they genuinely are not hungry. Tracking caloric intake during early protocol phases and maintaining a minimum floor — typically 1,200 to 1,500 calories depending on the patient — helps prevent the lean mass losses that come with severe energy restriction.

The Peptide Approach to Lean Mass

For patients who want to prioritize lean mass preservation alongside fat loss, certain peptide protocols pair well with GLP-1 therapy. Sermorelin and related growth hormone secretagogues support muscle preservation and recovery. BPC-157 supports tissue repair. These are complementary protocols — not substitutes for adequate protein and training, but meaningful additions for patients optimizing body composition beyond simple weight loss.

Your provider can advise on which combinations are appropriate for your goals and health history. The conversation starts with understanding that weight loss and optimal body composition are related but distinct objectives — and that achieving both requires more than the medication alone.